摘要
目的:分析盐酸替罗非班对行经皮冠状动脉介入治疗(PCI)的急性ST段抬高型心肌梗死(STEMI)患者临床疗效及NT-proBNP水平的影响。方法:收集本院2014年1月-2016年12月行PCI的STEMI患者79例临床资料进行回顾性分析。按照治疗方法不同分为对照组与观察组,对照组(n=38)行PCI治疗,观察组(n=41)在对照组基础上加用盐酸替罗非班。比较两组TIMI血流分级情况、ST段抬高回落效果、心功能指标、氨基末端脑钠肽前体(NT-proBNP)及主要心脏不良事件(MACE)发生率。结果:术后观察组TIMI血流分级明显优于对照组(P<0.05),观察组ST段抬高回落效果明显优于对照组(P<0.05)。术后4周,观察组左心室射血分数(LVEF)明显高于对照组,左心室收缩末期内径(LVESD)、心室舒张末期内径(LVEDD)及血清NT-ProBNP水平明显低于对照组(P<0.05)。观察组MACE发生率低于对照组(P<0.05)。结论:盐酸替罗非班可改善行PCI的STEMI患者冠脉血流和心肌再灌注,减少近期MACE的发生。
Objective:To analyze the effect of Tirofiban Hydrochloride on the clinical efficacy and NTproBNP level of acute ST-segment elevation myocardial infarction(STEMI)undergoing percutaneous coronary intervention(PCI).Method:Clinical data of 79 cases of STEMI patients underwent PCI in our hospital from January 2014 to December 2016 were collected for retrospective analysis.The control group(n=38)treated with PCI,and the observation group(n=41)treated with Tirofiban Hydrochloride on the basis of the control group.The blood flow grading of TIMI,the effect of ST-segment elevation drop,cardiac function index,amino-terminal pro-brain natriuretic peptide(NT-proBNP)and the incidence of major adverse cardiac events(MACE)were compared between the two groups.Result:Postoperative TIMI blood flow grading in the observation group was significantly better than that in the control group(P<0.05).The effect of ST-segment elevation drop in the observation group was significantly better than that in the control group(P<0.05).4 weeks after the operation,left ventricular ejection fraction(LVEF)of the observation group was significantly higher than the control group,and the left ventricular end systolic inner diameter(LVESD),end-diastolic inner diameter(LVEDD)and serum NT-proBNP levels of the observation group were significantly lower than those of the control group(P<0.05).The incidence of MACE in the observation group was lower than that in the control group(P<0.05).Conclusion:Tirofiban Hydrochloride can improve coronary blood flow and myocardial reperfusion in patients with STEMI undergoing direct PCI,and reduce the occurrence of MACE in the near future.
作者
廖启发
赵小瑞
LIAO Qifa;ZHAO Xiaorui
出处
《中国医学创新》
CAS
2020年第1期5-8,共4页
Medical Innovation of China
